Article
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.
Nature communications - 12 Jun 2020
Mouhieddine Tarek H, Sperling Adam S, Redd Robert, Park Jihye, Leventhal Matthew, Gibson Christopher J, Manier Salomon, Nassar Amin H, Capelletti Marzia, Huynh Daisy, Bustoros Mark, Sklavenitis-Pistofidis Romanos, Tahri Sabrin, Hornburg Kalvis, Dumke Henry, Itani Muhieddine M, Boehner Cody J, Liu Chia-Jen, AlDubayan Saud H, Reardon Brendan, Van Allen Eliezer M, Keats Jonathan J, Stewart Chip, Mehr Shaadi, Auclair Daniel, Schlossman Robert L, Munshi Nikhil C, Anderson Kenneth C, Steensma David P, Laubach Jacob P, Richardson Paul G, Ritz Jerome, Ebert Benjamin L, Soiffer Robert J, Trippa Lorenzo, Getz Gad, Neuberg Donna S, Ghobrial Irene M
Abstract excerpt
Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somatic mutations in the peripheral blood is termed clonal hematopoiesis of indeterminate potential (CHIP) and is associated with adverse outcomes. Targeted sequencing of the stem cell product from 629 MM...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.